Prostate cancers are characterized by progressive changes that render them increasingly aggressive, metastatic, hormone independent and resistant to treatment. The goal of this Program is to elucidate the alterations in signal transduction mechanism that underlie the progression of prostate cancer from benign, localized and androgen dependent to aggressive, disseminated and hormone independent. The Program brings together five productive and experienced investigators with important expertise relevant to the goals of this Program, three with a background in signal transduction and two with a background in prostate cancer biology and therapy. Michael J. Weber studies transducing kinase cascades regulated by Ras; Sarah J. Parsons studies signaling by protein kinases in the regulation of neuroendocrine cell growth and secretion; J. Thomas Parsons investigates integrin signaling; J. Thomas Parsons investigates integrin signaling; Charles E. Myers works on signal transduction as a therapeutic target for prostate cancer; and Leland W. K. Chung ha pioneered the development of prostate cell lines which reflect in vivo progression, and which are used by all the investigators. The Program gains from the participation of an expert Surgical Pathologist, Henry Frierson, who has begun specializing in prostate cancer and who will work with the investigators in the analysis of tissues from in vivo experiments and human samples. Project 1, J. Thomas Parsons and Leland W.K. Chung, Adhesion signaling in tumor cell progression will examine the repertoire of expressed and functional integrin molecules and the signaling pathways by which they control adhesion, motility and invasion of prostate cancer. Project 2, Michael J. Weber, Intracellular signaling and androgen independence will study the growth factor stimulated kinase cascades which can activate or bypass the androgen receptor. Project 3, Sarah J. Parsons and Charles E. Myers, Neuroendocrine cells in prostate cancer will analyze the differentiation and paracrine functions of neuroendocrine cells. Together, these projects cover critical areas which are fundamental to understanding tumor progression in prostate cancer, including events initiated at the cell surface, signals which operate intracellular and autocrine/paracrine growth regulatory products. This work should contribute significant significantly to the understanding, diagnosis, treatment and prevention of prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA076465-01A2
Application #
2824874
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mohla, Suresh
Project Start
1999-04-01
Project End
2004-01-31
Budget Start
1999-04-01
Budget End
2000-01-31
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Virginia
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
001910777
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Axelrod, Mark J; Mendez, Rolando E; Khalil, Ashraf et al. (2015) Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways. Head Neck 37:1722-32
DaSilva, John O; Amorino, George P; Casarez, Eli V et al. (2013) Neuroendocrine-derived peptides promote prostate cancer cell survival through activation of IGF-1R signaling. Prostate 73:801-12
Gioeli, Daniel; Wunderlich, Winfried; Sebolt-Leopold, Judith et al. (2011) Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer. Mol Cancer Ther 10:1581-90
Vomastek, Tomas; Iwanicki, Marcin P; Burack, W Richard et al. (2008) Extracellular signal-regulated kinase 2 (ERK2) phosphorylation sites and docking domain on the nuclear pore complex protein Tpr cooperatively regulate ERK2-Tpr interaction. Mol Cell Biol 28:6954-66
Casarez, Eli V; Dunlap-Brown, Marya E; Conaway, Mark R et al. (2007) Radiosensitization and modulation of p44/42 mitogen-activated protein kinase by 2-Methoxyestradiol in prostate cancer models. Cancer Res 67:8316-24
Deeble, Paul D; Cox, Michael E; Frierson Jr, Henry F et al. (2007) Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. Cancer Res 67:3663-72
Gioeli, Daniel; Black, Ben E; Gordon, Vicki et al. (2006) Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol 20:503-15
Gioeli, Daniel (2005) Signal transduction in prostate cancer progression. Clin Sci (Lond) 108:293-308
Fu, Maofu; Rao, Mahadev; Wu, Kongming et al. (2004) The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity. J Biol Chem 279:29436-49
Cooper, Carlton R; Sikes, Robert A; Nicholson, Brian E et al. (2004) Cancer cells homing to bone: the significance of chemotaxis and cell adhesion. Cancer Treat Res 118:291-309

Showing the most recent 10 out of 20 publications